

OVATION SCIENCE INC.

595 Burrard Street, Suite 1085, Box 201, Vancouver, British Columbia V7X 1M8

July 12, 2018

SKINVISIBLE PHARMACEUTICALS, INC.

6320 S. Sandhill Road, Suite 10
Las Vegas, Nevada, 89120 U.S.A.

Attention: Terry Howlett

Dear Sirs:

Re: US \$250,000 Promissory Note originally due on the earlier of the completion of an Initial Public Offering or March 31, 2018

On March 14, 2018 Skinvisible Pharmaceuticals, Inc. agreed to the extension of the due date on the above promissory note to the earlier of the completion of an Initial Public Offering or June 30, 2018.

On June 19, 2018 Skinvisible Pharmaceuticals, Inc. agreed to the extension of the due date on the above promissory note to the earlier of the completion of an Initial Public Offering or September 15, 2018.

On July 11, 2018 Ovation Science Inc. made a payment of US \$110,000 to Skinvisible Pharmaceuticals, Inc. against the amount due under the promissory note and Skinvisible Pharmaceuticals, Inc. agreed to the extension of the due date on the above promissory note to the earlier of the completion of an Initial Public Offering or September 30, 2018.


This will confirm our agreement that in consideration of \$1.00 and other good and valuable consideration, Skinvisible Pharmaceuticals, Inc. has agreed to further extend the due date of the balance of US \$50,000 owing on the Note to the earlier of the completion of an Initial Public Offering or September 30, 2018 as set out below:

| Original Payment Due Date | First Amended Payment Due Date | Second Amended Payment Due Date | Third Amended Payment Due Date | Amount |
|---|--|---|---|-------------|
| the earlier of the completion of an Initial Public Offering or March 31, 2018 | the earlier of the completion of an Initial Public Offering or June 30, 2018 | the earlier of the completion of an Initial Public Offering or September 15, 2018 | the earlier of the completion of an Initial Public Offering or September 30, 2018 | US \$50,000 |

Please sign where indicated below confirming our agreement.

OVATION SCIENCE INC.


per:


David K. Ryan
Director

Agreed and accepted this 12 day of July, 2018.

SKINVISIBLE PHARMACEUTICALS, INC.

per:


TERRY HOWLETT, Director & CEO